Condition
Non Small Cell Lung Cancer Metastatic
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 54 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
54 shownObservational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung CancerNCT07563205 · 2025-11-19
RECRUITINGPALACE: Cemiplimab Trial According to ctDNA LevelsNCT06917573 · 2025-07-29
RECRUITINGFirst-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)NCT07190677 · 2025-01-17
RECRUITINGA Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the BrainNCT06741085 · 2024-12-13
RECRUITINGA Phase Ib Study of GC101 in NSCLCNCT06473961 · 2024-10-14
RECRUITINGValue of Screening MRI Brain in Stage IV Non-small Cell Lung CancerNCT05864794 · 2024-05-13
RECRUITINGA Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on LorlatinibNCT06378892 · 2024-03-15
RECRUITINGA Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)NCT05657873 · 2022-12-09
RECRUITINGTreatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung DiseaseNCT07420439 · 2026-09-15
NOT_YET_RECRUITINGPhase III, Multicenter, Randomized Controlled Clinical Study of Three-Dimensional Radiotherapy for Primary Tumors in Non-Oligometastatic Stage IV Non-Small Cell Lung CancerNCT07462728 · 2026-03-30
NOT_YET_RECRUITINGSurvival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung CarcinomaNCT07111104 · 2024-10-14
COMPLETEDJDQ443 for KRAS G12C NSCLC Brain MetastasesNCT05999357 · 2024-04-15
WITHDRAWNEffect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICINCT06100796 · 2023-10-01
UNKNOWNDouble-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLCNCT05668650 · 2023-08-15
UNKNOWNLiquid Biopsy Based NGS in Newly Diagnosed NSCLCNCT05853887 · 2023-06-15
ACTIVE_NOT_RECRUITINGA Biomarker Screening Protocol for Participants With Solid TumorsNCT05891197 · 2023-05-19
TERMINATEDPembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)NCT05599789 · 2023-02-01
ACTIVE_NOT_RECRUITINGA Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)NCT05429320 · 2022-06-15
COMPLETEDA Study to Investigate LYL797 in Adults With Solid TumorsNCT05274451 · 2022-03-29
TERMINATEDFecal Microbial Transplantation Non-Small Cell Lung Cancer and MelanomaNCT04951583 · 2021-11-16
UNKNOWNSafety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerNCT05117242 · 2021-10-27
TERMINATEDLorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)NCT04621188 · 2021-03-19
ACTIVE_NOT_RECRUITINGStudy to Investigate DRP-104 in Adults With Advanced Solid TumorsNCT04471415 · 2020-08-31
TERMINATEDLorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung CancerNCT04111705 · 2020-08-05
COMPLETEDPharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male SubjectsNCT05110118 · 2020-08-04
COMPLETEDStudy of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR MutationNCT04233021 · 2020-07-16
COMPLETEDImmunological Profile Changes In Patients With Advanced Non-Small Cell Lung CancerNCT04187768 · 2019-11-26
COMPLETEDThyroid Dysfunction and Nivolumab Reponse in NSCLCNCT04470440 · 2019-10-22
COMPLETEDMarrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLCNCT04069936 · 2019-10-15
TERMINATEDAtezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel ChemotherapyNCT03977194 · 2019-07-23
ACTIVE_NOT_RECRUITINGHer2-positive Lung Cancer Treated With Dedicated DrugNCT03845270 · 2019-05-17
COMPLETEDPhase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerNCT03907852 · 2019-04-15
ACTIVE_NOT_RECRUITINGA Study to Evaluate Immunotherapy Combinations in Participants With Lung CancerNCT03846310 · 2019-04-01
COMPLETEDTemozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain MetastasesNCT03732482 · 2019-03-01
UNKNOWNPersonalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)NCT03715985 · 2019-01-28
UNKNOWNRandomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and LungNCT03808662 · 2019-01-16
ACTIVE_NOT_RECRUITINGPhase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerNCT03377023 · 2018-02-02
ACTIVE_NOT_RECRUITINGPD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung CancerNCT03774732 · 2018-01-24
ACTIVE_NOT_RECRUITINGA Study of ASN007 in Patients With Advanced Solid TumorsNCT03415126 · 2018-01-19
COMPLETEDA Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)NCT03353675 · 2018-01-05
COMPLETEDFirst-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2bNCT03319628 · 2017-12-12
ACTIVE_NOT_RECRUITINGFirst-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2bNCT06517433 · 2017-12-12
COMPLETEDA Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung CancerNCT03533127 · 2017-11-27
UNKNOWNImmunotherapy by Nivolumab for HIV+ PatientsNCT03304093 · 2017-10-19
COMPLETEDStudy of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042NCT03307785 · 2017-10-12
COMPLETEDRadiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)NCT03168464 · 2017-10-09
TERMINATEDCD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With NivolumabNCT03123783 · 2017-07-10
COMPLETEDCombining Radiosurgery and Nivolumab in the Treatment of Brain MetastasesNCT02978404 · 2017-06-02
COMPLETEDOsimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790MNCT03133546 · 2017-05-31
COMPLETEDCancer Panel From Blood of Lung Cancer PatientsNCT03235765 · 2017-03-10
UNKNOWNHypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung CancerNCT03035890 · 2017-01-23
COMPLETEDStereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung CancerNCT06207292 · 2016-12-01
UNKNOWNExercise Intervention During Chemotherapy in Advanced Lung Cancer PatientsNCT03334071 · 2014-04-04
UNKNOWN5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung CancerNCT01658813 · 2012-07-01
COMPLETEDCommon interventions
NivolumabDRUG7BevacizumabDRUG4CarboplatinDRUG4PembrolizumabDRUG4IpilimumabDRUG3LorlatinibDRUG3OsimertinibDRUG3PaclitaxelDRUG3ChemotherapyDRUG2LY01008DRUG2PemetrexedDRUG2RadiotherapyRADIATION2upifitamab rilsodotinDRUG25-Fluorouracil and InterferonDRUG1AcasunlimabBIOLOGICAL1Anti-PD-(L)1 based immunotherapyBIOLOGICAL1APX005MDRUG1ASN007 RDDRUG1ASN007: ascending dosesDRUG1AtezolizumabDRUG1atezolizumabBIOLOGICAL1Autologous Tumor Infiltrating LymphocytesBIOLOGICAL1AvastinDRUG1Blood collection to assess for ctDNAOTHER1Carboplatin-Nab-PaclitaxelDRUG1
Leading sponsors
Intergroupe Francophone de Cancerologie Thoracique
7
Memorial Sloan Kettering Cancer Center
4
Centre hospitalier de l'Université de Montréal (CHUM)
2
Lyell Immunopharma, Inc.
2
Mersana Therapeutics
2
Apexigen America, Inc.
1
Arcus Biosciences, Inc.
1
Asana BioSciences
1
Assiut University
1
Centro di Riferimento Oncologico - Aviano
1
Charu Aggarwal
1
Dracen Pharmaceuticals, Inc.
1
ETOP IBCSG Partners Foundation
1
Fondazione IRCCS Policlinico San Matteo di Pavia
1
Fundación GECP
1
Trial status mix
COMPLETED19
ACTIVE_NOT_RECRUITING9
UNKNOWN9
RECRUITING8
TERMINATED6
NOT_YET_RECRUITING2
WITHDRAWN1
Phase mix
PHASE229
PHASE114
NA6
PHASE35
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.